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Abstract
Melanoma is one of the most aggressive and less chemotherapy-responsive human cancers, representing a major public health issue
worldwide. The early diagnosis still represents the best approach in order to reduce mortality, especially in advanced stages.
Preclinical evidence, collected through several in vitro and in vivo models, has been accumulating about the pathophysiological
involvement of β-adrenoceptors in melanoma progression. This involvement has been paralleled by the evidence that drugs
blocking β-adrenoceptors (β-blockers) may have a relevant role in the treatment of melanoma and in the prevention of its
progression. β-blockers are a class of drugs extensively used in clinical practice, not limited to cardiovascular therapeutics.
Evidence collected through retrospective and prospective observational studies suggests that treatment with β-blockers, mainly
propranolol, is able to delay melanoma progression. Although conclusive evidence is still lacking, current knowledge proposes β-
blockers as an opportunity for antitumor treatment in melanoma. Clinical trials are needed in order to prove their claimed efficacy.
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Introduction
The incidence of skin cancers has been increasing over the
past decades. Currently, between 2 and 3 millions non-
melanoma skin cancers and 132,000 melanoma skin cancers
occur globally each year (WHO-Skin cancer 2019).
Melanoma is among the most aggressive and chemotherapy-
resistant human cancers, representing a major public health
problem worldwide. Although immunotherapy (e.g. tyrosine
kinase inhibitors, new immunotherapy agents) has expanded
treatment options for cancers with historically poor outcomes
like melanoma, a relevant proportion of patients still fail to
experience long-lasting clinical benefit. Early detection still
represents the best means to reduce mortality due to this tu-
mor, especially in advanced stages (Maverakis et al. 2015).
Over the last 30 years, a substantial body of clinical and
epidemiological research has linked psychosocial factors, in-
cluding stress, depression and lack of social support, with
cancer onset and progression (Sanzo et al. 2010; Jia et al.
2017; Spiegel 1994). Stress occurs when the organism per-
ceives a disruption or a threat of disruption of homeostasis
(Krizanova et al. 2016), and stress response is constituted by
the constant adaptation of the organism in order to maintain
the homeostasis in answer to changes in social and physical
environments (Goldstein 2003).While acute, short-term stress
is considered to have a positive effect on the body, chronic
stress is usually detrimental and may result in serious health
consequences. Prolonged stress is associated with dysregula-
tion of the hypothalamic-pituitary-adrenal axis, leading to an
increase in the production of cortisol and simultaneous eleva-
tions in catecholamines, i.e. adrenaline and noradrenaline
(Krizanova et al. 2016). The effects of catecholamines are
mediated through interactions with α- and β-adrenoceptors
(ARs). Many studies suggest that stress-related catechol-
amines overproduction might impact cancer prognosis and
mortality, affecting not only the antitumor immune response
(Marino and Cosentino 2013), but also displaying direct
tumor-promoting effects in breast, ovary, colorectal, esopha-
gus, lung, prostate, nasopharynx cancers, as well as in leuke-
mia and angiosarcoma (Tang et al. 2013). As shown by a large
body of preclinical evidence, β-ARs are widely involved in
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the regulation of these pro-tumorigenic cellular processes.
Their activation by catecholamines seems to stimulate cancer
cell proliferation, to induce anti-apoptotic processes, to pro-
mote angiogenesis and to facilitate migration, invasion and
adhesion of tumor cells, finally leading to metastasis (Tang
et al. 2013), Fig. 1. However, there is no firm conclusion that
β-ARs are the fundamental pathway on these processes. α -
ARs have been found in tumors, such as prostate cancer, ma-
lignant mesothelioma, thyroid medullary carcinoma, and
breast cancer, and their activation may affect cancer progres-
sion as well (Hirota 2016). The presence and the strength of
AR-mediated pro-tumorigenic mechanisms is influenced by
the quantity and subtype of AR expressed by each kind of
tumor. With regard to melanoma, functionalβ-ARs have been
found in this cancer (Yang et al. 2009; Moretti et al. 2013;
Calvani et al. 2015), while there is no similar evidence about
α-AR expression. Interestingly, each of the reported pro-
tumorigenic effects caused by β-adrenergic stimulation on
melanoma and microenvironment cells was reduced by a di-
rect blockade of β-ARs using their selective blocking agents
(Yang et al. 2009; Moretti et al. 2013; Calvani et al. 2015; Dal
Monte et al. 2013).
In the light of such promising laboratory data, many re-
searchers have suggested that the commonly prescribed class
of β-AR antagonist drugs, the β-blockers, may positively im-
pact on cancer survival. In the last few years, a growing number
of observational studies have supported the use ofβ-blockers as
an off-label adjuvant therapy capable of prolonging survival of
cancer patients, although some studies have put forward con-
troversial conclusions, as recently highlighted in three different
meta-analysis (Weberpals et al. 2016; Na et al. 2018; Yap et al.
2018). In dermatology, the use of β-adrenergic-blocking agents
has risen in popularity since the serendipitous discovery of their
efficacy in cases of severe infantile hemangiomas (Leaute-
Labreze et al. 2008). Similar to what observed in other cancer
types, the main results of cohort studies in patients affected by
melanoma seem to confirm the association between β-blocker
assumption and reduction of disease progression (De Giorgi
et al. 2011, 2013, 2017, 2018; Lameshow et al. 2011), despite
some discrepancies exist between the studies conducted so far
(Livingstone et al. 2013; McCourt et al. 2014). However, β-
blockers still cannot be considered as an alternative to tradition-
al therapy, as they are investigational, not yet have reached the
clinic with anti-cancer intent and even may be of value when
actually added to traditional therapy such as chemotherapy.
Taking into account the solid preclinical data, this review
aims to present the current clinical evidence about antitumor
efficacy of β-blockers in the treatment of melanoma, in order
to discuss whether these drugs can be considered an appropri-
ate therapeutic option for patients affected by this skin cancer.
Beta-Adrenergic System and Pharmacology
of β-Blockers
Adrenaline is synthetized from noradrenaline through demeth-
ylation by chromaffin cells in the adrenal medulla and released
in the bloodstream upon stimulation by the sympathetic ner-
vous system. Noradrenaline is a neurotransmitter in the central
and peripheral nervous system. At a central level, it is mainly
involved in the regulation of blood pressure by the vasomotor
center within the medulla, but also in the induction of wake-
fulness and state of alertness, and in the control of mood state
and pain circuits (pain descending control). In peripheral tis-
sues, noradrenaline is the main transmitter of sympathetic
postganglionic fibers (Katzung 2012; Coelho et al. 2017).
Catecholamines exert their actions by interacting with 7-
transmembrane, G protein-coupled receptors named ARs,
widely expressed in the target tissues. The general class of
AR is constituted by α- and β-AR types, each further
subdivided in subtypes. Three different β-AR receptors (β1,
β2 and β3-AR) have been identified in humans. Usually, β1-
AR are located close to sympathetic terminals and are targeted
mainly by noradrenaline released from nerves, while β2-AR
are often extrajunctional receptors and may be preferentially
activated by circulating noradrenaline and adrenaline. In
Fig. 1 Proposed mechanism of
β-adrenoceptors in cancer
progression and relative role
of β-blockers
particular, β-AR are expressed in heart (β1 and a few β2,
increasing force and rate of contraction), in skeletal muscle
(β2, inducing hypertrophy), and in vascular smooth muscle
and smooth muscular organs, such as bronchi, uterus, gastro-
intestinal tract and urinary bladder (β2, promoting relaxation).
β-AR are also implicated in metabolic and endocrine effects,
as far as β2-AR activation induces insulin and glucagon se-
cretion, liver gluconeogenesis and glycogenolysis, and mus-
cular glycogenolysis, while β1-AR activation determines re-
nin release by the juxtaglomerular cells of kidney (López-
Sendón et al. 2004. β3-AR, that are more sensitive to the
action of noradrenaline, are mainly expressed in brown adi-
pose tissue, where they activate lipolysis together with β1-
AR, and in skeletal muscle, where they contribute to thermo-
genesis (Balligand 2013). Beta2-AR are also expressed on
skin, where they can be found in secretory coil of apocrine
glands, keratinocytes, fibroblasts and melanocytes (Chen and
Tsai 2017).
Beta-blockers share the common feature of antagonizing
the effects of adrenergic stimuli on various organs. They re-
versibly bind β receptors and competitively reduce receptor
occupancy by catecholamines and other β agonists. On the
basis of the relative affinity for the different receptor subtypes,
β-blockers can be broadly classified into non-selective, those
producing a competitive blockade of both β1- and β2-AR,
and β1-selective, those with much higher affinity for the β1
than for the β2 receptors usually. However, since none of the
clinically available β-blockers are absolutely specific for β1
receptors, the selectivity is dose-dependent and decreases or
disappears when larger doses are used (Westfall and Westfall
2011). Few molecules (e.g. propranolol, nadololol,
levobunolol, bupranolol) have been shown to target β3-AR,
to this day (Bond et al. 2019). Although most of the effects of
β-blockers are due to β-AR blockade, some actions may be
due to other pharmacodynamic properties. Several selective or
non-selective β-blockers present peripheral vasodilator activ-
ity produced through different pathways, such as α1-AR
blockade, β2-agonism or mechanisms independent of the in-
teraction with ARs (i.e. release of nitric oxide, antioxidant
action, K+ channel opening, and Ca2 + entry blockade). Most
β-blocking drugs in clinical use are pure antagonists, but par-
adoxically some β-blockers exert a weak agonist response,
defined as partial agonism or intrinsic sympathomimetic ac-
tivity (ISA), and can moderately stimulate (in the absence of
catecholamines) and block (in the presence of high catechol-
amine concentrations) β-ARs (López-Sendón et al. 2004;
Baker 2005; Westfall and Westfall 2011) (Table 1).
Furthermore, evidence suggests that some β blockers (i.e.
propranolol, timolol) are inverse agonist drugs that reduce
constitutive activity of β-AR in some tissues (Chidiac et al.
1994) (see Table 1).
The differences in lipid solubility influences the pharmaco-
kinetic profile of various β-blockers. Lipophilic drugs (e.g.
metoprolol, propranolol, timolol) are rapidly and completely
absorbed from the gastrointestinal tract and extensively me-
tabolized in the gut wall and in the liver (first pass effect), so
that their oral bioavailability is low (10–30%). They present
short elimination half-lives (1–5 h) and easily enter the central
Table 1 Main pharmacologicaland pharmacokinetic properties of β-blockers (Westfall and Westfall 2011; López-Sendón et al. 2004)
β-blocker ISA Vasodilator activity Lipid solubility Absorption
(%)
Oral bioavailability
(%)
Plasmatic
half-life (hours)
Non-selective β-blockers
Nadolol 0 Low 30 30–50 20–24
Penbutolol + High/Moderate ~ 100 ~ 100 ~ 5
Pindolol +++ Low/High > 95 ~ 100 3–4
Propranolol 0 High < 90 30 3–5
Timolol 0 Low-moderate/High 90 75 4
Carvedilol 0 α1-AR blockade, antioxidant activity,
Ca2 + entry blockade
Moderate > 90 ~ 30 7–10
Labetalol + α1-AR blockade Low > 90 ~ 33 3–4
Selective β1-blockers
Acebutolol + Low/Moderate 90 20–60 3–4
Atenolol 0 Low 90 50–60 6–7
Bisoprolol 0 Moderate ≤90 80 9–12
Esmolol 0 Low NA NA 0.15
Metoprolol 0 High ~ 100 40–50 3–7
Celiprolol 0 Release of NO, β2-AR agonism Moderate ~ 74 30–70 5
Nebivolol 0 Release of NO Low NA NA 11–30
AR adrenoceptor, ISA intrinsic sympathomimetic activity, NA not available, NO nitric oxide
nervous system, which may account for a greater incidence of
central side-effects. Hydrophilic β-blockers (e.g. atenolol,
esmolol) that are absorbed incompletely from the gastrointes-
tinal tract, are excreted unchanged or as active metabolites by
the kidney. These molecules have longer half-lives, and barely
cross the blood-brain barrier (López-Sendón et al. 2004;
Westfall and Westfall 2011) (Table 1).
The major pharmacological effects of β-blockers are doc-
umented in the cardiovascular system, with important differ-
ences between the effects induced in the heart in healthy sub-
jects at rest versus in conditions of stress, such as exercise or
the presence of cardiovascular disease. In the context of car-
diovascular diseases, these drugs have proved to be effective
in hypertension, stable and acute coronary artery disease,
hearth failure and cardiac arrhythmias. Since their arrival on
the clinical scene in 1960s, the breadth of β-blockers has
expanded to include, inter alia, treatment of migraine, essen-
tial tremor, glaucoma, and control of somatic symptoms of
hyperthyroidism and anxiety (Westfall and Westfall 2011).
Although β-blockers are generally well tolerated, side-
effects may occur, especially when these agents are used at
larger doses. Common side effects include bradycardia, re-
duced capability to exercise, impotence and loss of libido,
constipation or diarrhea. Sometimes patients note cold hands
and feet. Central effects, such as fatigue, headache, insomnia
and vivid dreams, are less common with hydrophilic mole-
cules. Beta-blockers are contraindicated in patients with asth-
ma or bronchospastic chronic obstructive pulmonary disease
owing to concerns that these medications may trigger increase
of airway resistance, and in people affected by diabetes, since
β-blockers may mask warning symptoms of hypoglycemic
episodes, such as tremor and tachycardia (López-Sendón
et al. 2004; Westfall and Westfall 2011; Katzung 2012).
β-Blockers and Cancer
The first finding corroborating the involvement of β-AR in
cancer proliferation was the evidence that, on the one side,
isoprenaline, a non-selective β-AR agonist, induces lung ad-
enocarcinoma cell proliferation and, on the other side, pro-
pranolol contrasts the effect of β-AR stimulation (Schuller
and Cole 1989). In the following years, evidence has been
accumulating about similar properties in other types of cancer,
including angiosarcoma, breast, colorectum, hemangiomas,
leukemia, lung, melanoma, nasopharynx, esophagus, ovary,
pancreas, prostate and stomach (Tang et al. 2013).
Importantly from a therapeutic point of view, β-blockers
may be effective in contrasting cancer development and pro-
gression. First, in rodent models of neuroblastoma, either non-
selective or selective β- blockers have been shown to boost
the response to chemotherapy (Pasquier et al. 2013). Second,
in an ovarian carcinoma mouse model, propranolol impairs
the β2-AR-mediated growth of cancer cells induced by in-
creased noradrenaline associated with chronic stress (Thaker
et al. 2006). Similarly, in a prostate cancer mouse model,
selective β2-AR blockade prevents the tumor growth favored
by surgical stress (Hassan et al. 2013). Third, propranolol
prevents tumor development in a mouse model of lung cancer
(Min et al. 2016); it also suppresses proliferation and promotes
apoptosis in hemangioma cells, similar to selective β2-AR
blockers, but not selective β1-AR blockers (Munabi et al.
2016). A more relevant role for β2-AR in comparison to
β1-AR is suggested also in other cancer models, as pancreatic
cancer cell line invasiveness and proliferation are more effi-
ciently blocked by β2-AR blockers than by β1-AR blockers
(Zhang et al. 2010) and in a model of prostate cancer, β2-AR
knockout mice in which the lack of β2-AR inhibits tumor
progression (Zahalka et al. 2017).
Beta-Blockers and Melanoma
One seminal paper suggesting peculiar features of melanoma
in comparison to other tumors regarding influences of cate-
cholaminergic system is the oldest one retrieved searching the
PubMed with the terms “melanoma” AND “noradrenaline”
or “melanoma” AND “norepinephrine”. The paper by Edlich
et al. (Edlich et al. 1966) showed that, in rodents, changes in
melanoma blood flow secondary to catecholamine infusion
were more pronounced than those in the proximal skin and
muscle. In particular, it was shown that the administration of
low doses of adrenaline and noradrenaline was associated
with a relevant reduction in tumor blood flow associated with
unvaried skin blood flow. Similarly, the administration of
higher doses of both substances reduced perfusion to all tis-
sues, with much greater effects in the melanoma tissue. These
results differentiated melanoma from other neoplasms (i.e.
sarcoma and carcinoma) that were found to behave like nor-
mal tissue by other authors (Guillino and Grantham 1961,
1962). Importantly, it was already known that, as observed
in mice through a transparent membrane inserted in a skin
flap, the vascular system of the carcinoma and sarcoma was
made of randomly sinusoidal channels of large diameter with
no evidence of arterioles and venules, while melanoma had a
quite organized vessel system with thinner capillaries and
evidence of differentiation into arterioles and venules
(Algire and Legallais 1951, 1958). Although initial sugges-
tions emerging from evidence were primarily dealing with
vessel anatomy and physiology, data collected since that re-
mote beginning compose a more complex scenario in which
catecholamines, and hence β-blockers, may exert differential
effects in melanoma that may be exploited for therapeutic
purposes. The following sections of the review will present
evidence according to its preclinical (i.e. in vitro, in vivo) or
clinical nature and will draw conclusion emerging from cur-
rent knowledge on the field.
Preclinical Evidence
Preclinical evidence has been collected by means of different
experimental approaches and models, spanning from cell lines
to in vivo animal model.
In Vitro
β-Adrenoceptors
Benign melanocytic nevi, atypical nevi and malignant melano-
mas express β1- and β2-ARs, with expression significantly
higher in the latters (Rains et al. 2017). Immunohistochemistry
assay has shown the presence of β1- and β2-ARs in cell lines
(C8161, 1174MEL, Me18105) and in primary and metastatic
human melanoma biopsies (Yang et al. 2009). Importantly, nor-
adrenaline upregulates production of (vascular endothelial
growth factor) VEGF, interleukin-6 (IL-6) and interleukin-8
(IL-8), in cell lines by both β1 and β2 ARs (Yang et al. 2009).
Accordingly, human A375 primary melanoma cell line and hu-
man Hs29-4 T metastatic melanoma cell lines have been shown
to express β1- and β2-ARs, measurable as both transcripts and
proteins (Moretti et al. 2013); a previous binding study in the
melanoma cell line A-375 has concluded that cells express a
homogeneous population of β2-adrenoceptors. (Steinkraus
et al. 1990). Noteworthy, β3-AR expression in mouse B16F10
melanoma cells was demonstrated (Dal Monte et al. 2013) and
more importantly from a therapeutic point of view, immunohis-
tochemical research ofβ1-ARs,β2-ARs, andβ3-ARs across 29
of the most common human cancers (389 tissues total) and 19
matching non-cancer controls (100 tissues total) has proven that
all threeβ-AR receptors, and in particularβ3-AR receptors, were
expressed most strongly in melanoma in comparison to other
cancers (Rains et al. 2017). Recently, it has been also shown that
β3-AR promotes a metabolic shift, with accelerated glycolysis
and reduced mitochondrial activity, in both melanoma and em-
bryonic stem cells, through the induction of uncoupling protein 2
(UCP2). In particular, the β3-AR/UCP2 axis induces a strong
reduction of mitochondrial activity by reducing ATP synthesis
and mitochondrial reactive oxygen species (mtROS).
Importantly, β3-AR have been demonstrated within the mito-
chondrial membrane in melanoma cells, where they can control
ofmitochondrial dormancy (Calvani et al. 2018). In addition,β3-
ARs are expressed in vivo in stromal, inflammatory and vascular
cells of the melanomamicroenvironment. It has been shown that
the coexistence ofβ3-AR inmelanoma and accessory cells is the
substrate needed to drive melanoma cells responses to environ-
mental stimuli, to increase melanoma cells responses to macro-
phages and stromal fibroblasts, to promote melanoma cell
motility and to induce stem-like traits. Noteworthy, β3-AR acti-
vation in melanoma accessory cells induces pro-inflammatory
cytokines secretion and neoangiogenesis that support tumor
growth and melanoma aggressiveness (Calvani et al. 2015).
β3-ARs also play a pivotal role in the recruitment of circulating
stromal cells precursors, in their differentiation towards different
lineages, further favoring inflammation and angiogenesis, thus
melanoma aggressiveness (Calvani et al. 2015).
β-Blockers
Several studies investigated the effects of β-blockers in mel-
anoma cell proliferation and invasiveness. Propranolol has
been shown to inhibit the increased metalloprotease-
dependent motility and the release of IL-6, IL-8 and VEGF
induced by adrenaline and noradrenaline. (Moretti et al. 2013)
In addition, propranolol has been shown to inhibit prolifera-
tion and induces apoptosis in primary cell cultures derived
from human melanoma, both primary tumour and metastasis,
and in melanoma cell lines (A375, Mewo, and Mel-CLS3)
(Wrobel and Le Gal 2015). It is noteworthy that the
cardioselective β-blocker metoprolol tartrate is not able to
affect melanoma cell survival or proliferation to the same ex-
tent (Wrobel and Le Gal 2015). Propranolol has been exten-
sively tested on the A375 melanoma cell line, two primary
acral melanoma cell lines (P-3, P-6) and mice xenografts.
Propranolol was able to inhibit viability of the different mel-
anoma cell lines in a concentration and time dependent man-
ner but had no effect on immortalized keratinocyte cell line. In
addition, propranolol has been demonstrated to activate the
intrinsic apoptosis pathway and inactivate the MAPK and
AKT pathways, as it reduces the expression of Bcl-2, in-
creases the expressions of Bax, cytochrome c, cleaved
capase-9 and cleaved caspase-3, and down-regulated the
levels of p-AKT, p-BRAF, p-MEK1/2 and p-ERK1/2 (Zhou
et al. 2016). A better understanding of β-AR subtypes in-
volvement in melanoma emerged from the use of selective
antagonists. In order to unravel the role of β3-ARs in mouse
B16F10 melanoma cells, after demonstrating β3-AR expres-
sion, the effects of β3-AR blockers (SR59230A and
L-748,337) were evaluated vs. propranolol or siRNAs
targeting specific β-ARs. Beta3-blockers, likely via NO path-
way, reduced cell proliferation, induced apoptosis and, differ-
ently form propranolol (Glasner et al. 2010) prevented the
hypoxia-induced VEGF upregulation (Dal Monte et al. 2013).
SR59230A, a specific β3-AR antagonist, counteracts the
abovementioned metabolic shift with an increase in mtROS
(Calvani et al. 2018). Notably, in embryonic stem cells, the
increased mtROS are neutralized by a strong antioxidant ac-
tivity, while in cancer stem cells this neutralization does not
take place, with consequent reduction in tumor cell viability
(Calvani et al. 2018).
Initial evidence has been collected about the role of biased
agonists, such as carvedilol, which are able to exert some ac-
tivity as β-arrestin activators while blocking the β-ARs. In
particular carvedilol has been shown to exert antiproliferative
action on several tumoral cell lines, including melanoma Fem-x
(Stanojkovic et al. 2005), and to be able to prevent the growth
of A375 malignant melanoma xenografts in mice (Cleveland
et al. 2018). On the other hand, some contrasting evidence
emerged about the possible role of the β2-AR, which when
activated by (R,R’)-4′-methoxy-1-naphthylfenoterol has been
shown to inhibit proliferation and motility of melanoma cells
(Wnorowski et al. 2015).
In Vivo
Recent evidence suggests thatβ2-AR signaling in host immune
cells orchestrates CD8+ T cell frequency and functional orien-
tation within the tumor microenvironment. Evidence collected
by means of different approaches aimed at reducing adrenergic
activation (i. manipulation of ambient thermal environment; ii.
β-blockers, iii. β2-AR knockout mice) in mouse models of
melanoma show that the decrease of β-AR signaling favored
the conversion of tumors to an immunologically active micro-
environment with increased frequency of effector CD8+ Tcells,
with relatively increased ratio to CD4+ regulatory T cell ratio
(IFNγ+CD8+:Treg), and decreased expression of programmed
death receptor-1 (PD-1) (Bucsek et al. 2017). Importantly, these
features were associated with an increased efficacy of anti-PD-1
checkpoint blockade (Bucsek et al. 2017).
In B16F10 cells, neither isoprenaline nor propranolol affected
cancer cell proliferation. Importantly, in B16F10 melanoma-
bearing mice propranolol behaves as an antiproliferative accord-
ing to a U-shaped biphasic dose-response curve. Low doses (10
and 20 mg·kg−1 ·day−1) significantly inhibit tumor growth, while
higher doses exert progressively less effects. In addition, high-
dose propranolol stimulatesmelanoma arteriogenesis but with no
effect on angiogenesis at any dose (Maccari et al. 2017). In
immunodeficient mice transplanted with humanmelanoma cells,
daily treatment with propranolol slows down tumor development
(Wrobel and Le Gal 2015). According to RNA microarrays,
quantitative PCR, and histochemistry findings, propranolol af-
fects the expression of several genes involved in tumor angio-
genesis, cell death, and proliferation (Wrobel and Le Gal 2015).
Propranolol has been also investigated in the MT/Ret mouse
model of melanoma, where its administration delayed primary
tumor growth and metastases development, likely by decreasing
cell proliferation and vessel density in both primary tumors and
metastases (Wrobel et al. 2016). In addition, propranolol on the
one side, reduced the infiltration of neutrophils in the tumor and,
on the other side increased cytotoxic tumor infiltrating lympho-
cytes in the tumor stroma, with a similar pattern in both primary
and secondary lesions (Wrobel et al. 2016). Daily treatment with
propranolol has been shown to inhibit melanoma growth in
A375 xenografts where it also reducedKi67, inhibited phosphor-
ylation of AKT, BRAF, MEK1/2 and ERK1/2, thus activating
the intrinsic apoptosis pathway and inactivating the MAPK and
AKT pathways (Zhou et al. 2016). Furthermore, the growth of
melanoma induced in mice by inoculation of B16F10 cells, was
similarly reduced by intra-tumor injections of β3-blockers
SR59230A or L-748,337 that reduce cell proliferation and stim-
ulate apoptosis that involves also endothelial cells and, conse-
quently, decrease tumor vascularization (Dal Monte et al. 2013).
Finally, some evidence suggests synergistic anti-melanoma
effects of propranolol with other drugs. First, it has been
shown that the coadministration with etodolac is able to im-
prove survival rates in C57BL/6 J mice were inoculated
intrafootpad with syngeneic B16F10.9-melanoma, and to act
as immunostimulant (Glasner et al. 2010; Goldfarb et al.
2011). Second, in a cell viability assay of A375 and P8 MM
cell lines it has been shown a significant decrease of sunitinib
IC50 when combined with propranolol (Kuang et al. 2017).
Propranolol and sunitinib combination significantly down-
regulated phospho-Rb, phospho-ERK, Cyclin D1, and
Cyclin E, with no effect on Bax, Bcl-2, or cleaved PARP
expression. In A375 xenografts, combination of propranolol
and low-dose sunitinib reduced the average tumor size of
treated mice similar to high-dose sunitinib treated (Kuang
et al. 2017). Some studies have also afforded the hypothesis
that, similar to what observed in vitro, also in vivo differentβ-
AR subtypesmay exert differential roles. In a murinemodel of
B16 melanoma it has been shown that, β1/2-AR knockout
mice displayed increased intratumoral levels of both noradren-
aline and β3-ARs, increased tumor vascularization, decreased
tumor cell proliferation and increased tumor cell apoptosis
(Sereni et al. 2015). Importantly,β1/2-AR knockout mice also
showed increased responsiveness to the intralesional injection
the β3-blocker L-748,337 (decrease in tumor growth, tumor
vascular response, tumor cell proliferation, increase in tumor
cell death) (Sereni et al. 2015). Importantly, in a mouse model
of metastatic melanoma (B16-F10 melanoma cells transfected
with red fluorescent protein, injected intravenously into
syngenic C57BL/6 J mice to generate lung and liver metasta-
ses), plasma levels of adrenocorticotropin hormone, cortico-
sterone and noradrenaline increased following a circadian pat-
tern, being the two latters able to increase in vitro the expres-
sion and secretion of IL-6 in B16-F10 cells. In vivo inocula-
tion of B16-F10 cells transfected with anti-IL-6-siRNA, treat-
ment with a glucocorticoid receptor blocker or with propran-
olol, increased hepatic GSH while decreasing plasma IL-6
levels and metastatic growth (Valles et al. 2013).
Clinical Evidence
The possible impact of β-blockers on cancer progression and
diffusion has been quite extensively investigated in last years.
According to a recent review, searching for studies published
up to September 1, 2017 and including 36 studies, which
involve 319,006 patients, there was no evidence of an associ-
ation between β-blocker use and overall survival, all-cause
mortality, disease-free survival, progression-free survival,
and recurrence-free survival. Notwithstanding, β-blocker use
was significantly associated with longer overall survival only
in melanoma (HR = 0.81, 95% CI: 0.67–0.97), ovarian and
pancreatic cancer and better cancer-specific survival for sev-
eral cancer types (HR = 0.78, 95% CI: 0.65–0.95), including
melanoma (Na et al. 2018). In a meta-analysis on β-blocker
use and cancer prognosis, where studies which were deemed
to include immortal time bias were not considered, a signifi-
cantly higher overall survival (HR 0.81, 95% CI 0.69–0.96)
among melanoma patients was observed. However, there was
no melanoma-specific survival advantage (HR 0.92, 95% CI
0.74–1.15). This finding suggests that the potential beneficial
effects of β-blockers might primarily reflect non-cancer relat-
ed positive effects, for instance on the course of cardiovascular
comorbidities (Weberpals et al. 2016).
Up to date, no results have been collected through trials and
our current knowledge is mainly founded on few retrospective
observational studies (Table 2). Initial evidence has emerged
from the observation that the use of β-blockers for concomi-
tant diseases is associated with a reduced risk of progression
of thick (Breslow thickness > 1 mm) melanoma. In the co-
horts, 30 patients had been prescribed β-blockers for 1 year
or more, whereas the other 91 were untreated. After a median
follow-up time of 2.5 years, tumor progression was observed
in 3.3% of the treated subgroup and in 34.1% of the untreated
subgroup, with 36% (95% confidence interval (CI), 11%–
54%) (P = .002) risk reduction for each year of β-blocker
use. It is noteworthy that no deaths were observed among
patients who have taken β-blocker, in comparison to the 24
deaths registered among untreated patients (De Giorgi et al.
2011). After a median follow-up of 8 years of the two cohorts,
with a median exposure to β-blocker use of 7.6 years, 30% of
the patients in the treated group vs. 45% in the untreated group
showed disease progression. Importantly, even after longer
follow up the initial finding about the difference in deaths
was observed, as in the treated group only 17% patients died
from melanoma vs. 35% in the untreated group (De Giorgi
et al. 2017). The finding was confirmed by the same Authors
investigating a larger population, including all consecutive
patients diagnosed with melanoma between January 1993
and December 2009. Of the 741 consecutive patients with
melanoma, 79 (11%) were prescribed β-blockers for 1 or
more years and 662 (89%) were not untreated. The treated
group had improved overall survival after a median follow-
up of 4 years (P = .005). For each year of β-blocker use, the
risk of death was reduced by 38% (De Giorgi et al. 2013).
More recently, a first prospective study has been performed
administering off-label propranolol in patients treated for mel-
anoma. Patients with histologically confirmed stage IB to IIIA
cutaneous melanoma and no evidence of metastasis were con-
sidered eligible. At diagnosis, they were asked to take pro-
pranolol (80 mg daily) as an off-label adjuvant treatment.
Patients who agreed to use the propranolol enter the propran-
olol cohort, those who refused entered the no-propranolol co-
hort. Among the 53 patients included in the study, 19 entered
the propranolol cohort, while 34 were enrolled in the no-
propranolol cohort. The use of propranolol at the time of di-
agnosis was inversely associated with recurrence of melano-
ma, with risk reduction close to 80% for propranolol cohort
(hazard ratio (HR), 0.18; 95% CI, 0.04–0.89; P = .03) after a
median follow up of 3 years (De Giorgi et al. 2018). Similar
findings were obtained retrieving data from Danish Cancer
Registry and medical and administrative databases, including
Table 2 Main characteristics of clinical studies investigating the impact of β-blockers on melanoma
Study design Study direction Country Source of data Sample size Follow up time
(median, years)
Reference
Findings supporting a benefit from β-blocker treatment
Cohort Retrospective Italy Clinical charts 121 2.5 De Giorgi et al. 2011
Cohort Retrospective Denmark Administrative database 4179 4.9 Lemeshow et al. 2011
Cohort Retrospective Italy Clinical charts 741 4 De Giorgi et al. 2013
Cohort Retrospective Italy Clinical charts 121 7.6 De Giorgi et al. 2017
Cohort Retrospective US Registry 195 Not reported Kokolus et al. 2017
Cohort Prospective Italy Clinical charts 53 3 De Giorgi et al. 2018
Findings not supporting a benefit from β-blocker treatment
Cohort Retrospective Germany/The Netherlands Administrative
database/registry
709 3,25 Livingstone et al. 2013
Case- control Retrospective Northern Ireland/UK Administrative
database/registry
1876 7.5 McCourt et al. 2014
Case-control Retrospective US Clinical charts 159 NR Failing et al. 2016
4179 patients diagnosed with malignant melanoma. A total of
372 (8.9%) patients with malignant melanoma were treated
with β-blockers within 90 days of melanoma diagnosis.
After adjustment for age and comorbidity index, HR for mel-
anoma death was 0.87 (95% CI: 0.64–1.20) and for all-cause
mortality was 0.81 (95% CI: 0.67–0.97) (Lemeshow et al.
2011).More recently, similar to preclinical results, a retrospec-
tive study has shown that metastatic patients who received
immunotherapy had improved overall survival if they also
received β-blockers (Kokolus et al. 2017).
It is worth noting that also negative findings have been
reported. In a case-control study based on the U.K. Clinical
Practice Research Datalink and cancer registry data, patients
who received a new melanoma diagnosis between 1998 and
2010 were included. Cases, represented by patients with ma-
lignant melanoma with a melanoma-specific death, were
matched on year of diagnosis, age and sex to four malignant
melanoma controls. A nested case-control approach was used
to investigate the association between postdiagnostic β -
blocker use and mortality. β-blockers were prescribed after
melanoma diagnosis to 20.2% of 242 cases and 20.3% of
886 matched controls with no association between β-blocker
use postdiagnosis and cancer-specific death or all-cause mor-
tality (McCourt et al. 2014). In addition, a study analyzing
data from the Eindhoven Cancer Registry between January
1, 1998 and December 31, 2010, who were also registered
with PHARMO record linkage system, identified a cohort of
adult patients with cutaneousmelanoma (Breslow thickness >
1 mm) who were matched on age and gender served as a
control cohort. Two hundred and three of 709 eligible patients
used β-blockers after melanoma diagnosis and the use of β-
blockers was not associated with the risk of death
(Livingstone et al. 2013). More recently, in a case control
study including 159 adults who received ipilimumab for met-
astatic melanoma from 1 March 2011 through 31 December
2014, β-blockers, similar to other drugs, seemed to have no
effects on the odds of experiencing a partial response or a
complete response to ipilimumab (Failing et al. 2016).
Conclusions
Preclinical and clinical evidence has been accumulating about
the involvement of β-ARs in melanoma progression. This
involvement has been paralleled by the evidence that drugs
targeting, read blocking, β-ARs may have a relevant role in
the treatment of melanoma and in the control of its progres-
sion. Current knowledge proposes β-blockers as an opportu-
nity for antitumor treatment in melanoma on the basis of pos-
itive findings collected in few observational studies, mostly
performed in small cohorts of patients. It is important to un-
derline that evidence collected by means of observational
studies are, for intrinsic methodological reasons, affected by
limitations and biases, such as selection bias (e.g. loss to fol-
low up, confounding by indication) and more importantly
immortal time bias. Accordingly, large double-blinded, ran-
domized, clinical trials are needed in order to prove (or dis-
prove) their claimed efficacy, identifying appropriate para-
digms of treatment (e.g. type ofβ-blocker to be used, duration
of administration, specific subtype of melanoma to be treated).
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